Title
Erythrasma: A report of nine men successfully managed with mupirocin 2% ointment monotherapy

Permalink
https://escholarship.org/uc/item/9zh116s1

Journal
Dermatology Online Journal, 23(5)

Authors
Greywal, Tanya
Cohen, Philip R

Publication Date
2017

License
CC BY-NC-ND 4.0

Peer reviewed
Erythrasma: A report of nine men successfully managed with mupirocin 2% ointment monotherapy

Tanya Greywal MD, Philip R Cohen MD

Affiliations: Department of Dermatology, University of California San Diego, San Diego, California

Corresponding Author: Tanya Greywal, MD, 9767 Alto Drive, La Mesa, CA 91941 Email: tgreywal@gmail.com, Philip R. Cohen, MD, 10991 Twinleaf Court, San Diego, CA 92131, Email: mitehead@gmail.com

Keywords: erythrasma, mupirocin, ointment, treatment

Introduction

Erythrasma is a benign dermatosis with characteristic clinical appearance. Systemic or topical antibiotics can be used to successfully treat this condition [1]. We describe nine men with erythrasma whose dermatoses resolved after application of mupirocin 2% ointment monotherapy.

Abstract

Background: Erythrasma is a benign dermatosis that typically occurs on intertriginous skin. Purpose: We describe a series of nine men with erythrasma that were successfully treated with mupirocin 2% ointment monotherapy. Methods and Materials: We reviewed PubMed for the following terms: erythrasma, mupirocin, ointment, treatment. We also reviewed papers containing these terms and their references. Results: Complete resolution of erythrasma occurred following monotherapy with twice daily application of mupirocin 2% ointment. Conclusions: Several topical and oral treatments are available to successfully manage erythrasma. Our series of patients with erythrasma experienced resolution with mupirocin 2% ointment treatment within 2 to 4 weeks of therapy. Monotherapy with mupirocin 2% ointment should be considered as a primary treatment alternative for erythrasma.

Case Series

Erythrasma was diagnosed in nine men whose clinical characteristics are summarized in Table 1. The morphology of each lesion was similar and consistent with erythrasma: red and red-brown plaques with scale on skin folds. Final diagnosis was confirmed by coral red fluorescence on Wood's lamp examination. Our patients’ ages ranged from 32 to 80 years, with a mean age of 58 years. Most of the lesions were located on the inguinal folds (Figures 1, 2); some extended onto the medial thighs (cases 1, 2, 4, and 8), (Figure 2), whereas one patient also experienced involvement of his axillae (case 7), (Figure 3). In addition, most of the patients had other medical conditions that were most likely a reflection of their age and not a predisposing factor to erythrasma. All of the patients were treated with mupirocin 2% ointment twice daily monotherapy with resolution of their erythrasma within 2 to 4 weeks of therapy. There was no treatment-associated folliculitis.

Case Discussion

Erythrasma is a superficial skin infection that most commonly presents in warm, moist, and occluded environments such as skin folds [2-5]. This disease is present worldwide, and is most prevalent in warm climates and during the summer months when higher humidity levels exist [2, 5]. Erythrasma does not have a predilection for any particular gender or race, but it is more common in elderly, diabetic, and obese patients [2, 4-6].

Erythrasma typically presents as discrete red-brown plaques and patches with minimal scale [2-8]. These lesions generally affect skin folds where
Figure 1. An 80-year-old man with erythrasma (case 9). A red plaque with scale is present on the left inguinal fold (A) with coral red fluorescence on Wood’s lamp examination (B).

Figure 2. A 69-year-old man with erythrasma (case 8) presented with red plaques with scale on the bilateral inguinal folds and medial thighs (A). Wood’s lamp showed coral red fluorescence (B).

Figure 3. A 64-year-old man with erythrasma involving the bilateral inguinal folds and axillae (case 7). A red-brown plaque was present in the right axilla (A) with a positive Wood’s lamp examination (B).
Table 1. Clinical characteristics of nine men with erythrasma.

<table>
<thead>
<tr>
<th>Case</th>
<th>Age (years)</th>
<th>Location</th>
<th>Other Medical Conditions</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>32</td>
<td>Bilateral inguinal folds and medial thighs</td>
<td>None</td>
</tr>
<tr>
<td>2</td>
<td>49</td>
<td>Bilateral inguinal folds and medial thighs</td>
<td>Trigeminal neuralgia</td>
</tr>
<tr>
<td>3</td>
<td>51</td>
<td>Bilateral inguinal folds</td>
<td>Type 1 diabetes</td>
</tr>
<tr>
<td>4</td>
<td>54</td>
<td>Bilateral inguinal folds and medial thighs</td>
<td>Hyperlipidemia</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Benign essential tremor</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Gastroesophageal reflux disease</td>
</tr>
<tr>
<td>5</td>
<td>60</td>
<td>Bilateral inguinal folds</td>
<td>Hypertriglyceridemia</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hyperlipidemia</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Generalized anxiety disorder</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Sciatica</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Sleep apnea</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Allergic rhinitis</td>
</tr>
<tr>
<td>6</td>
<td>63</td>
<td>Bilateral inguinal folds</td>
<td>None</td>
</tr>
<tr>
<td>7</td>
<td>64</td>
<td>Bilateral inguinal folds and axillae</td>
<td>None</td>
</tr>
<tr>
<td>8</td>
<td>69</td>
<td>Bilateral inguinal folds and medial thighs</td>
<td>Arthritis</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hyperlipidemia</td>
</tr>
<tr>
<td>9</td>
<td>80</td>
<td>Bilateral inguinal folds</td>
<td>Parkinson’s Disease</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Monoclonal gammopathy of unknown significance</td>
</tr>
</tbody>
</table>

1 All the men were Caucasian. The morphology of all lesions was similar, consisting of red-brown plaques and coral red fluorescence on Wood’s lamp examination.

there is occlusion and a warm, moist environment [2, 4, 5, 7, 8]. Patients may experience pruritus and lichenification secondary to scratching, but many are often asymptomatic [2, 3, 5, 7, 8].

The diagnosis of erythrasma is classically based upon clinical presentation [3]. A Wood’s lamp examination is especially important since it can confirm the diagnosis; it emits ultraviolet A radiation, which reveals the coral red fluorescence of porphyrins produced by Corynebacterium species [2, 3, 7, 8]. Coproporphyrin III is the porphyrin that is most commonly produced in patients with erythrasma, with some reports of uroporphyrin I or other porphyrin involvement [6, 9]. However, it is important to remember that Wood’s lamp examination may be negative in patients with erythrasma, particularly when the patient recently washed and temporarily cleared the porphyrins in the area of involvement [3]. In these cases, a biopsy, although not frequently performed, may yield the diagnosis. If tissue is obtained, hematoxylin-eosin stain will likely show normal-appearing skin since this infection does not produce a significant inflammatory reaction nor is the organism easily observed in the upper layers of the epidermis [2, 3, 6]. Instead, special stains such as periodic acid-Schiff, methenamine silver, and gram stain can allow the small coccobacilli to be observed in the superficial stratum corneum [2, 3, 6]. In addition, some studies have attempted to culture erythrasma fluorescent scales, and they demonstrated that the organism had specific requirements for the culture medium [10-12]. Therefore, a bacterial swab may be able to provide sufficient organism for culture. However, it might require confirmation with the microbiology lab to make sure that the specimen is plated on appropriate medium. The differential diagnosis of erythrasma includes candidiasis, dermatophytosis, intertrigo, pityriasis (tinea) versicolor, psoriasis, and terra firma-forme dermatosis [2, 4, 13, 14].

Erythrasma is caused by a gram-positive bacterial organism: Corynebacterium species [1-4, 7, 8, 15]. Corynebacterium minutissimum is most commonly implicated, with few reports showing the involvement of other Corynebacterium species, such as C. aurimucosum and C. jeikeium; one study isolated Microbacterium oxydans (a coryneform
gram-positive rod) [1-4, 7-9, 15-17]. Corynebacterium minutissimum is a non-spore-forming and facultatively anaerobic bacillus that thrives in warm, moist, and occlusive environments that promote bacterial proliferation [2, 15]. In addition, Corynebacterium species are involved not only in pitted keratolysis of the plantar feet, but also in trichobacteriosis of the axilla (trichomycosis axillaris) [2, 18].

The treatment of erythrasma is directed by the bacterial microorganism present. Oral antibiotics or topical antibiotics or a combination of both are typically used [1-5, 7, 8]. Commonly used oral antibiotics include clarithromycin, erythromycin, and tetracycline [1, 2, 5, 7]. Topical antibiotic therapies include clindamycin, erythromycin, and sodium fusidate [2-4, 6-8].

Mupirocin is a topical antibiotic that is usually used to treat Streptococcus and Staphylococcus infections, including methicillin-resistant Staphylococcus aureus. To the best of our knowledge, there are no previous reports of mupirocin 2% ointment monotherapy used to treat erythrasma. However, mupirocin 2% ointment has been successfully used in the setting of pitted keratolysis, a benign dermatosis that is also caused by a Corynebacterium species infection [19-21].

Promoted by these observations in patients with pitted keratolysis, we elected to also treat our patients with erythrasma with mupirocin 2% ointment monotherapy. Our patients’ lesions completely resolved after 2 to 4 weeks of treatment and had not recurred when they were evaluated during follow-up appointments.

Conclusion
Erythrasma presents as red-brown plaques and patches on intertrigenous skin and it is associated with a Corynebacterium species infection. Management typically includes topical or oral antibiotics to which these gram-positive organisms are susceptible. Our patients’ erythrasma resolved within 2 to 4 weeks after initiation of monotherapy with mupirocin 2% ointment. We respectfully suggest that twice daily application of mupirocin 2% ointment monotherapy be considered as first line treatment for erythrasma.

References